Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

V3388

Sigma-Aldrich

Vascular Endothelial Growth Factor (aa 207-318) human

≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder

Synonyme(s) :

VEGF112, Vasculotropin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Numéro MDL:
MFCD00286542
Code UNSPSC :
12352202
Nomenclature NACRES :
NA.32

product name

Vascular Endothelial Growth Factor (aa 207-318) human, ≥97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder

Source biologique

human

Niveau de qualité

100

Produit recombinant

expressed in E. coli

Pureté

≥97% (SDS-PAGE)

Forme

lyophilized powder

Puissance

0.75-3.75 ng/mL ED50

Poids mol.

predicted mol wt ~28 kDa

Conditionnement

pkg of 5 μg

Conditions de stockage

avoid repeated freeze/thaw cycles

Impuretés

<1 EU/μg

Numéro d'accès UniProt

P15692

Température de stockage

−20°C

Informations sur le gène

human ... VEGFA(7422)

Application

Vascular Endothelial Growth Factor (aa 207-318) human also known as VEGF 121 was used for preparing a cellular matrix hybridized with hyaluronic acid (ACM-HA) VEGF constructs which is used in measuring the VEGF-enhanced tissue-engineered bladder graft neovascularization by using dynamic contrast-enhanced MRI. The product was used for creating VEGF-impregnated tissue-engineered construct which was inserted in the critical-sized calvarial defect in the membranous parietal bone of the rabbit for examining and characterizing the angiogenesis necessary for bone formation.

Actions biochimiques/physiologiques

Vascular Endothelial Growth Factor (aa 207-318) human also referred to as VEGF 121 or Vasculotropin is a basic protein that induces endothelial cell growth, vasculogenesis and angiogenesis. VEGF also enhances the growth of endothelial cells isolated from cerebral cortex, fetal and adult aorta as well as human umbilical vein. Cells enhance VEGF 121 secretion from fibrin implants results in local and controlled blood vessel growth.
Potent angiogenesis inducer in vivo.

Autres remarques

112 amino acid residue variant of human VEGF.

Forme physique

Lyophilized from a 0.2 μm filtered solution in 30% acetronitrile and 0.1% TFA containing 0.25 mg bovine serum albumin.

Remarque sur l'analyse

The biological activity is measured by its ability to stimulate 3H-thymidine incorporation in human umbilical vein endothelial cells.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Martin Ehrbar et al.
Circulation research, 94(8), 1124-1132 (2004-03-27)
Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF
Marine Beaumont et al.
NMR in biomedicine, 23(1), 48-55 (2009-08-04)
Tissue engineering is a promising technique for bone repair and can overcome the major drawbacks of conventional autogenous bone grafting. In this in vivo longitudinal study, we proposed a new tissue-engineering paradigm: inserting a biological soft-tissue construct within the bone
Molecular and biological properties of the vascular endothelial growth factor family of proteins.
N Ferrara et al.
Endocrine reviews, 13(1), 18-32 (1992-02-01)
Leung, D.W., et al.
Science, 246 (1989)
Lisa Cartwright et al.
Journal of biomedical materials research. Part A, 77(2), 390-395 (2006-01-24)
Tissue engineered organs require an immediately perfused vascular tree. Currently, neovascularization assessment requires animal sacrifice and graft harvest. In this pilot study we assess whether neovascularization of an engineered urinary bladder construct is enhanced with vascular-derived endothelial growth factor (VEGF)
Afficher tous les articles scientifiques apparentés

Articles

Vascular Endothelial Growth Factors (VEGF)

VEGF-A stimulates blood vessel growth via endothelial cell proliferation, migration, and survival during embryonic development.

Vascular Endothelial Growth Factors (VEGF)

VEGF-A stimulates blood vessel growth via endothelial cell proliferation, migration, and survival during embryonic development.

Vascular Endothelial Growth Factors (VEGF)

VEGF-A stimulates blood vessel growth via endothelial cell proliferation, migration, and survival during embryonic development.

Vascular Endothelial Growth Factors (VEGF)

VEGF-A stimulates blood vessel growth via endothelial cell proliferation, migration, and survival during embryonic development.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique